Loading

Nivalis CFO: IPO proceeds will fund company well into Phase 3 trial program

BizWest – Nivalis Therapeutics Inc. chief financial officer Michael Carruthers said Thursday that the company will reap in the “low $70 million range” in net proceeds from Wednesday’s initial public offering once standard commissions and fees are paid.  More info